000078341 001__ 78341 000078341 005__ 20200217133051.0 000078341 0247_ $$2doi$$a10.1016/j.drudis.2018.01.031 000078341 0248_ $$2sideral$$a105480 000078341 037__ $$aART-2018-105480 000078341 041__ $$aeng 000078341 100__ $$0(orcid)0000-0002-0269-7337$$aRuiz-Pesini, E.$$uUniversidad de Zaragoza 000078341 245__ $$aIncreasing mtDNA levels as therapy for mitochondrial optic neuropathies 000078341 260__ $$c2018 000078341 5060_ $$aAccess copy available to the general public$$fUnrestricted 000078341 5203_ $$aLeber hereditary optic neuropathy (LHON) is a rare, inherited mitochondrial disease. No treatment has shown a clear-cut benefit on a clinically meaningful end-point. Primary open-angle glaucoma (POAG) is a frequent, acquired optic neuropathy. Lowering intraocular pressure (IOP) reduces disease progression. However, current methods to decelerate this progression are recognized as being inadequate. Therefore, there is a clear need to look for new therapeutic approaches. The growing evidence indicates that POAG can also be a mitochondrial optic neuropathy (MON). Several risk elements are common for both diseases and all of them decrease mitochondrial (mt)DNA content. Based on these susceptibility factors and their molecular mechanism, we suggest herein pharmacological therapies targeted to increase mtDNA levels, oxidative phosphorylation (OXPHOS) capability, and mitochondrial energy production as treatments for MONs. 000078341 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B33$$9info:eu-repo/grantAgreement/ES/DGA/FEDER$$9info:eu-repo/grantAgreement/ES/ISCIII/PI14-00070$$9info:eu-repo/grantAgreement/ES/ISCIII/PI17-00021$$9info:eu-repo/grantAgreement/ES/ISCIII/PI17-00166$$9info:eu-repo/grantAgreement/ES/ISCIII/P114-00005 000078341 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/ 000078341 590__ $$a6.88$$b2018 000078341 591__ $$aPHARMACOLOGY & PHARMACY$$b12 / 266 = 0.045$$c2018$$dQ1$$eT1 000078341 592__ $$a2.248$$b2018 000078341 593__ $$aPharmacology$$c2018$$dQ1 000078341 593__ $$aDrug Discovery$$c2018$$dQ1 000078341 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000078341 700__ $$0(orcid)0000-0001-5964-6138$$aEmperador, S.$$uUniversidad de Zaragoza 000078341 700__ $$0(orcid)0000-0002-3217-1424$$aLópez-Gallardo, E.$$uUniversidad de Zaragoza 000078341 700__ $$0(orcid)0000-0003-3524-5158$$aHernández-Ainsa, C.$$uUniversidad de Zaragoza 000078341 700__ $$0(orcid)0000-0003-1770-6299$$aMontoya, J.$$uUniversidad de Zaragoza 000078341 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología 000078341 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole. 000078341 773__ $$g23, 3 (2018), 493-498$$pDrug discov. today$$tDRUG DISCOVERY TODAY$$x1359-6446 000078341 8564_ $$s420347$$uhttps://zaguan.unizar.es/record/78341/files/texto_completo.pdf$$yPostprint 000078341 8564_ $$s43759$$uhttps://zaguan.unizar.es/record/78341/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000078341 909CO $$ooai:zaguan.unizar.es:78341$$particulos$$pdriver 000078341 951__ $$a2020-02-17-12:42:55 000078341 980__ $$aARTICLE